Plain-English translation of NCT05114096 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Babies born early are at high risk of serious breathing and health problems. This trial is testing whether Celestone—a steroid medication that helps babies' lungs develop—works just as well with a single dose as it does with the standard two doses. If you qualify, you'll receive one dose as part of normal care, then be randomly assigned to either receive a placebo injection or a second dose of the medication.
Doctors have been giving two doses of this medication to pregnant people at risk of early delivery for many years, but no one has ever studied whether one dose might work just as well—or even be safer. This trial will help answer that question so doctors can give the best care with the fewest injections.
You likely qualify if…
You likely don't qualify if…
You will have already received your first steroid injection as part of standard pregnancy care. Then, about 24 hours later, you'll receive a second injection—either the real steroid medication (standard care) or a placebo saline injection (the experimental approach being tested). Your baby will be monitored closely throughout your pregnancy and after birth to track their health and development.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Canada